Next 10 |
home / stock / bovnf / bovnf news
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China Nat...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development...
LUND, SWEDEN / ACCESSWIRE / May 24, 2024 / BioInvent International (STO:BINV) TNFR2 and FcyRIIB are promising targets in immuno-oncology. BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class im...
First data for the SC arm : 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients. Further updates from the IV arm; a fifth CR has been observed, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients. Data to be presented at ...
LUND, SWEDEN / ACCESSWIRE / May 3, 2024 / BioInvent International (STO:BINV) The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to elect Laura Lassouw-Polman as new Board member, to re-elect the Board members Natalie Berner, Kristoffe...
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahe...
LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been pu...
Agreement covers Phase 1/2a trial with TNFR2 agonist antibody BI-1910 First data from BI-1910 single agent arm expected by YE 2024 LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the di...
News, Short Squeeze, Breakout and More Instantly...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China Nat...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development...